Table 2 Change in outcomes over time after second allogeneic stem cell transplantation.
Outcomes | Total | 2000–2004 | 2005–2009 | 2010–2014 | 2015–2019 |
|---|---|---|---|---|---|
Estimation (95 CI %) | Estimation (95 CI %) | Estimation (95 CI %) | Estimation (95 CI %) | Estimation (95 CI %) | |
Median FU (y) | 4.9 (4.3–5.6) | 15.1 (7.2–16.3) | 11 (9.7–11.8) | 6.9 (6.3–7.2) | 2.5 (2.2–2.8) |
OS (2 y) | 31.2 (28.8–33.7) | 22.5 (16–29.6) | 26.4 (21.9–31.2) | 32.9 (28.3–37.6) | 35 (30.8–39.2) |
LFS (2 y) | 22.2 (20–24.4) | 14.5 (9.2–20.9) | 18.7 (14.7–23) | 24.5 (20.3–28.8) | 24.5 (20.8–28.4) |
RI (2 y) | 53.5 (50.9–56.1) | 64 (55.3–71.4) | 55.1 (49.7–60.2) | 52.6 (47.6–57.4) | 50.7 (46.3–54.9) |
NRM (2 y) | 24.3 (22.1–26.6) | 21.5 (15.1–28.8) | 26.2 (21.7–31) | 22.9 (18.9–27.1) | 24.8 (21.3–28.4) |
aGVHD-II/IV (100 d) | 31.7 (29.3–34.2) | 30.2 (22.5–38.3) | 36.1 (30.9–41.3) | 32.2 (27.6–36.9) | 29.1 (25.4–33) |
aGVHD-III/IV (100 d) | 15.5 (13.6–17.4) | 13.2 (8–19.6) | 16.1 (12.3–20.3) | 17.6 (14–21.5) | 14.2 (11.5–17.3) |
GRFS (2 y) | 15.5 (13.7–17.5) | 10.5 (6.2–16.1) | 12.6 (9.4–16.4) | 17.5 (14–21.4) | 17 (13.9–20.5) |
cGVHD (2 y) | 28.2 (25.9–30.7) | 24.8 (17.7–32.5) | 27.8 (22.9–32.8) | 32.6 (28–37.4) | 25.7 (22–29.5) |
cGVHD Ext (2 y) | 12.4 (10.7–14.2) | 10.9 (6.2–17) | 12.1 (8.8–16.1) | 13.6 (10.3–17.3) | 12 (9.3–15) |
